C
Cyclacel Pharmaceuticals Inc 6 Convertible Preferred Stock
Healthcare
· Common: CYCC
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company that develops cancer medicines based on cell cycle, epigenetics, and mitosis biology, operating in the United States and the United Kingdom. Its lead programs include fadraciclib, a cyclin-dependent kinase (CDK) inhibitor in Phase 1/2 trials for solid tumors and hematological malignancies, and Plogosertib, a polo-like kinase inhibitor also in Phase 1/2 trials for advanced solid tumors and hematological malignancies. The company is small-cap, with a market capitalization of approximately $13.5 million.
1 Exchange-Traded Security
| Symbol | Type | Coupon | Price | Yield | Call Date | |
|---|---|---|---|---|---|---|
| CYCCP | preferred | 6.000% | 5.05 | 11.88% | 2007-11-06 |